A Gut Feeling for Metformin.
Metformin is a first-line glucose-lowering agent in patients with type 2 diabetes (T2D). Recently in Nature Medicine, Sun et al. (2018) reported that short-term metformin therapy decreases gut Bacteroides fragilis, consequently increasing glycoursodexoycholic acid (GUDCA) levels in humans. As an antagonist of FXR, GUDCA may carry therapeutic potential in the treatment of T2D.